H3 Biomedicine Inc

Kyorin Pharmaceutical Co., Ltd. will shut down its US subsidiary ActivX Biosciences Inc. by the end of March 2023, saying the California bioventure, acquired for $21m in 2004, had made valuable con

Eisai Co., Ltd. has decided to shut down its US research subsidiary H3 Biomedicine Inc in September as part of a wider restructuring of its global R&D organization. According to an official notice

Evolution of clinical trials was a major theme among executives who at the end of 2021 shared their predictions for 2022. Remote, or decentralized, trials was a common talking point, as was the harnes